KRAS and neoplasm: Recent data indicated that, while a certain variability exists in terms of the anti-tumor responses to genetic ablation or pharmacological inhibition of KRAS [22,64,65,66], the targeting of KRAS still remains a great therapeutic opportunity, especially in the context of combination therapies that may circumvent cell-specific resistance.